这期刊本来还可以的，就比cancer research差一点点。然而不知道怎么回事，最近几年版面费大涨，发文量也增加了一倍，吸引了大量的中国投稿，目前中国人文章占比也猛升至30%。
目前这期刊确实比以前好投了，影响因子也长了，性价比高。然而代价是口碑变差了，近几年大量中国人灌水文章在上面发表，导致有一些大佬开始鄙视这个期刊，如果申请基金简历写这个可能会被专家认为灌水。

11 8

6月25号，所有审稿人分配，目前毫无消息

1 0

有人知道这是啥情况吗，是不是可以准备投别的杂志了？ Stage Start Date EIC Decision Started 30th Jun 21 Editor Review Completed 30th Jun 21 Waiting for Potential Reviewer Assignment 21st Jun 21 Monitoring Editor Assigned 21st Jun 21 Potential Monitoring Editor Assigned 21st Jun 21 Under Consideration 21st Jun 21 Editor Assigned 17th Jun 21 Author Approved Converted Files 17th Jun 21 Submission 17th Jun 21

2 1

去年通讯了一篇，感觉比较严谨，抓细节。改了两个月，接收。新颖性和意义要求比不上cancer res，但总体差距不大。

5 0

偏重的研究方向： Molecular cancer ; Oncology
经验分享：二月中旬投稿，七月中旬最终接收，三个审稿人，两次审稿，数据量比较大，不歧视小单位令人好评，国内好点的期刊投稿被要求注明来自哪个大团队，我们这些没山头的青年博士一投稿就被拒，审都不让审，关键是期刊里边同类型的文章有的也还不如我，sad

135 0

无

4 0

影响因子:9.87
经验分享：ONCOGENE的2020年度#影响因子#为9.867

158 1

有人遇到过这种情况吗？等待送审后是EIC决定。这是没送审还是系统里没更新其他通知EIC Decision Started 23rd Mar 21
Editor Review Completed 23rd Mar 21
Waiting for Potential Reviewer Assignment 3rd Mar 21
Monitoring Editor Assigned 3rd Mar 21
Potential Monitoring Editor Assigned 3rd Mar 21
Under Consideration 1st Mar 21
Editor Assigned 26th Feb 21
Author Approved Converted Files 26th Feb 21
Submission 26th Feb 21

16 4

偏重的研究方向：肿瘤
经验分享：最新影响因子 9.867分

8 0

审稿速度:2.0 | 投稿命中率:50.0 | 影响因子:6.0
偏重的研究方向：Cancer
经验分享：Waiting for Potential Reviewer Assignment 6th May 21
Monitoring Editor Assigned 6th May 21
Potential Monitoring Editor Assigned 6th May 21
Under Consideration 6th May 21
Editor Assigned 5th May 21
Author Approved Converted Files 5th May 21
Submission 5th May 21
前天投了一篇Review，请教各位大神

7 1